Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

Bob Valamehr, President and Chief Executive Officer of Fate Therapeutics

“Jamie is an accomplished commercial leader, and we are delighted to welcome him to Fate Therapeutics. His in-depth knowledge of the autoimmune landscape and years of direct interaction with rheumatologists, combined with his work on launching multiple indications for Remicade, building the in-office infusion model, and his recent work accelerating voclosporin for the treatment of lupus nephritis, will be invaluable as we drive to shape a new treatment paradigm for autoimmune disease.”

Jamie Harrell, Senior Vice President, Market Development & Commercial Operations at Fate Therapeutics

“I am honored to join Fate Therapeutics and lead the path for commercialization at such a pivotal moment for the company. Throughout my career, I’ve had the privilege of launching first‑in‑class therapies that reshape standards of care, and I am deeply committed to improving the lives of people suffering from complex rheumatologic conditions and cancers. CAR T-cell therapy represents a true revolution for autoimmune medicine, and Fate’s programs stand at the forefront of that transformation, uniquely providing outpatient administration and broad access to patients in need. In fact, the potential for in‑office infusion within community rheumatology practices is extraordinary, expanding access, usability, and equity for those who need it most. I’m thrilled to help bring this potentially transformative therapy and approach forward and to work alongside the Fate team to deliver a new era of care for patients.”